You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東音股份(002793.SZ):羅欣藥業一類新藥LX-086片獲准開展臨牀試驗
格隆匯 05-11 15:59

格隆匯5月11日丨東音股份(002793.SZ)公佈,近日,羅欣藥業下屬子公司山東羅欣和上海羅欣申報的1類新藥LX-086片獲得國家藥品監督管理局的臨牀試驗默示許可。LX-086為公司研發的PI3Kα選擇性抑制劑,擬用於晚期實體瘤的治療。目前國內尚無同類藥物上市。

與常規的泛PI3K抑制劑不同,LX-086特異性作用於PI3K蛋白α亞基,靶向性更好。LX-086通過抑制PI3K-Akt-mTOR信號通路,進而抑制腫瘤細胞的過度增殖,達到治療各種實體腫瘤的目的,同時還能避免影響PI3K蛋白其它亞基的正常功能,從而減少藥物安全性風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account